NasdaqCM - Delayed Quote USD

PolyPid Ltd. (PYPD)

4.3600

-0.1400

(-3.11%)

At close: June 7 at 4:00 PM EDT

PolyPid Ltd. (NASDAQ:PYPD) Q1 2024 Earnings Call Transcript

PolyPid Ltd. (NASDAQ:PYPD) Q1 2024 Earnings Call Transcript May 9, 2024 PolyPid Ltd. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Thank you all for participating in PolyPid’s First Quarter 2024 Earnings Conference Call. Joining me on the call today […]

Insider Monkey 29 days ago

PYPD
-3.11%
PolyPid Provides Corporate Update and Reports First Quarter 2024 Financial Results

More Than 200 Patients Enrolled in Ongoing SHIELD II Phase 3 Trial of D-PLEX100 for the Prevention of Abdominal Colorectal Surgical Site Infections Approximately 50 Centers Currently Open Unblinded Interim Analysis to be Conducted Once Approximately 400 Patients Complete Their 30-Day Follow-up; Top-line Results Expected in Second Half of 2024 Conference Call Scheduled for Today at 8:30 AM ET PETACH TIKVA, Israel, May 08, 2024 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Com

GlobeNewswire last month

PYPD
-3.11%
PolyPid to Participate in Citizens JMP Life Sciences Conference

PETACH TIKVA, Israel, May 01, 2024 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that company management will present at the Citizens JMP Life Sciences Conference taking place in New York, NY, from May 13 – 14, 2024. Citizens JMP Life Sciences Conference PresentationDate: Monday, May 13, 2024Time:2:30 PM ET The PolyPid management team will participate in one-on-one investor meeting

GlobeNewswire last month

PYPD
-3.11%
PolyPid Announces Enrollment of 200th Patient in Ongoing SHIELD II Phase 3 Trial Evaluating D-PLEX₁₀₀ for the Prevention of Abdominal Colorectal Surgical Site Infections

Study Approximately Half Enrolled to the Planned Unblinded Interim Analysis Unblinded Interim Analysis to be Conducted Once Approximately 400 Patients Complete Their 30-Day Follow-up Top-line Results Expected in Second Half of 2024 PETACH TIKVA, Israel, April 30, 2024 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it has enrolled the 200th patient in its ongoing SHIELD II Phase

GlobeNewswire last month

PYPD
-3.11%
PolyPid to Report First Quarter 2024 Financial Results and Operational Highlights on May 8, 2024

PETACH TIKVA, Israel, April 24, 2024 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it will report its first quarter 2024 financial results and operational highlights before the open of the U.S. financial markets on Wednesday, May 8, 2024. The Company will host a conference call and webcast at 8:30 AM Eastern Time to discuss the results and provide an update on business operati

GlobeNewswire last month

PYPD
-3.11%
PYPD: Polypid is Enhancing Surgical Outcomes

NASDAQ:PYPD VIEW THE FULL PYPD PROFILE PolyPid (NASDAQ:PYPD) is a global late clinical-stage biopharma company that specializes in developing, producing, and selling innovative therapies to enhance surgical results. The company’s PLEX (Polymer-Lipid Encapsulation matriX) technology is a distinct system that is applied at the surgical site to offer controlled and continuous medication release.

Zacks Small Cap Research last month

PYPD
-3.11%
PolyPid to Participate in Barclays 26th Annual Global Healthcare Conference

PETACH TIKVA, Israel, Feb. 28, 2024 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD), (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that Company management will participate in a fireside chat at the Barclays 26th Annual Global Healthcare Conference taking place in Miami Beach, FL, March 12 – 14, 2024. Barclays 26th Annual Global Healthcare Conference Fireside Chat Date: Thursday, March 14, 2024Time:7:30 – 7:55 AM ET The PolyPid m

GlobeNewswire 3 months ago

PYPD
-3.11%
PolyPid Ltd. (PYPD) Upgraded to Buy: What Does It Mean for the Stock?

PolyPid Ltd. (PYPD) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Zacks 3 months ago

PYPD
-3.11%
PolyPid Ltd. (NASDAQ:PYPD) Q4 2023 Earnings Call Transcript

PolyPid Ltd. (NASDAQ:PYPD) Q4 2023 Earnings Call Transcript February 14, 2024 PolyPid Ltd. misses on earnings expectations. Reported EPS is $-3.97 EPS, expectations were $-2.17. PolyPid Ltd. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Greeting morning and welcome to […]

Insider Monkey 3 months ago

PYPD
-3.11%
PolyPid Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results

More Than 100 Patients Enrolled in Ongoing SHIELD II Phase 3 Trial of D-PLEX100 for the Prevention of Abdominal Colorectal Surgical Site Infections Unblinded Interim Analysis to be Conducted Once Approximately 400 Patients Complete Their 30-Day Follow-up; Top-line Results Expected in Second Half of 2024 New Preclinical Data Showed OncoPLEX Injected Intratumorally Reduced Tumor Volume and Improved Survival in New Animal Models Recent Successful $16 Million Financing Extends Company’s Cash Runway

GlobeNewswire 3 months ago

PYPD
-3.11%
PolyPid Announces Enrollment of the 100th Patient in the Ongoing SHIELD II Phase 3 Trial

Approximately 40 Centers Currently Open Unblinded Interim Analysis to be Conducted Once Approximately 400 Patients Complete Their 30-Day Follow-up; Top-line Results Expected in Second Half of 2024 Recent Successful $16 Million Financing Extends Company’s Cash Runway Through Late Q3 2024 and Beyond Expected Timing of Unblinded Interim Analysis; Potential Additional $19 Million if Warrants are Exercised to Fund PolyPid to the Start of a Planned New Drug Application Submission for D-PLEX100 PETACH

GlobeNewswire 3 months ago

PYPD
-3.11%
PolyPid to Report Fourth Quarter and Full-Year 2023 Financial Results and Operational Highlights on February 14, 2024

PETACH TIKVA, Israel, Jan. 31, 2024 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it will report its fourth quarter and full-year 2023 financial results and operational highlights before the open of the U.S. financial markets on Wednesday, February 14, 2024. The Company will host a conference call and webcast at 8:30 AM Eastern Time to discuss the results and provide an update

GlobeNewswire 4 months ago

PYPD
-3.11%
PolyPid Announces Private Placement for $16 Million in Gross Proceeds

Financing Led by Leading U.S. Life Sciences-focused InvestorsPETACH TIKVA, Israel, Jan. 04, 2024 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it has entered into a securities purchase agreement for a private placement financing (the “PIPE”) for $16.2 million in gross proceeds priced at the 5-day volume weighted average price as of January 2, 2024 of $4.81 per share. The PIPE

GlobeNewswire 5 months ago

PYPD
-3.11%
PolyPid Ltd. (NASDAQ:PYPD) Q3 2023 Earnings Call Transcript

PolyPid Ltd. (NASDAQ:PYPD) Q3 2023 Earnings Call Transcript November 12, 2023 Operator: Thank you all for participating in PolyPid’s third quarter 2023 earnings conference call. Joining me on the call today will be Dikla Czaczkes Akselbrad, Chief Executive Officer of PolyPid; Jonny Missulawin, PolyPid’s Chief Financial Officer; and Ori Warshavsky, Chief Operating Officer of PolyPid. […]

Insider Monkey 6 months ago

PYPD
-3.11%
PolyPid Provides Corporate Update and Reports Third Quarter 2023 Financial Results

Total of 20 Centers Currently Open with Approximately 40 Expected by End of 2023 in SHIELD II Phase 3 Trial Evaluating D-PLEX100 for the Prevention of Abdominal Colorectal Surgical Site Infections Completed Production and Release of Three Process Validation Batches of D-PLEX100 Successful Completion of Good Manufacturing Practice Audit of Company’s Manufacturing Facility Conference Call Scheduled for Today at 8:30 AM ET PETACH TIKVA, Israel, Nov. 08, 2023 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq

GlobeNewswire 6 months ago

PYPD
-3.11%
PolyPid Announces the Addition of Dr. Nurit Tweezer-Zaks to its Board of Directors

Biopharmaceutical Industry Veteran Nurit Tweezer-Zaks, M.D., M.B.A. Appointed to Board Following Retirement of Anat Tsour SegalPETACH TIKVA, Israel, Nov. 07, 2023 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced the appointment of Nurit Tweezer-Zaks, M.D., M.B.A, to its Board of Directors, effective November 6, 2023, following the retirement of Anat Tsour Segal. Dr. Tweezer-Zaks is a

GlobeNewswire 6 months ago

PYPD
-3.11%
PolyPid to Report Third Quarter 2023 Financial Results and Operational Highlights on November 8, 2023

PETACH TIKVA, Israel, Nov. 01, 2023 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it will report its third quarter 2023 financial results and operational highlights before the open of the U.S. financial markets on Wednesday, November 8, 2023. The Company will host a conference call and webcast at 8:30 AM Eastern Time to discuss the results and provide an update on business ope

GlobeNewswire 7 months ago

PYPD
-3.11%
PolyPid Regains Compliance with Nasdaq Minimum Closing Bid Price Rule

PETACH TIKVA, Israel, Oct. 11, 2023 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it has received a written notice from The Nasdaq Stock Market LLC ("Nasdaq") that the Company has regained compliance with the minimum bid price requirement for continued listing set forth in Nasdaq Listing Rule 5550(a)(2), which requires listed securities, including the Company's ordinary shares

GlobeNewswire 7 months ago

PYPD
-3.11%
PolyPid Announces Presentation at the American College of Surgeons Clinical Congress 2023

PETACH TIKVA, Israel, Oct. 09, 2023 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that SHIELD I Phase 3 clinical data for D-PLEX100 will be highlighted in a presentation at the American College of Surgeons Clinical Congress 2023, to be held on October 22-25, 2023, in Boston, MA. American College of Surgeons Clinical Congress 2023 Presentation Title: Impact of Locally Applied Doxycy

GlobeNewswire 7 months ago

PYPD
-3.11%
PolyPid Announces Publication of Preclinical Data Further Supporting the Good Safety Profile of D-PLEX₁₀₀ and PLEX Technology Platform

Safety Profile of D-PLEX100 and PLEX Platform Shown in Juvenile Animals for the First Time Results Could Support Clinical Evaluation of D-PLEX100 in Pediatric Population PETACH TIKVA, Israel, Oct. 04, 2023 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced the publication of positive preclinical results demonstrating, for the first time, the safety profile of D-PLEX100 and the PLEX tech

GlobeNewswire 8 months ago

PYPD
-3.11%

Performance Overview

Return	PYPD	S&P 500
YTD	+14.74%	+12.10%
1-Year	-65.80%	+24.82%
3-Year	-98.44%	+26.41%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

PolyPid Ltd. (PYPD)

PolyPid Ltd. (NASDAQ:PYPD) Q1 2024 Earnings Call Transcript

PolyPid Provides Corporate Update and Reports First Quarter 2024 Financial Results

PolyPid to Participate in Citizens JMP Life Sciences Conference

PolyPid Announces Enrollment of 200th Patient in Ongoing SHIELD II Phase 3 Trial Evaluating D-PLEX₁₀₀ for the Prevention of Abdominal Colorectal Surgical Site Infections

PolyPid to Report First Quarter 2024 Financial Results and Operational Highlights on May 8, 2024

PYPD: Polypid is Enhancing Surgical Outcomes

PolyPid to Participate in Barclays 26th Annual Global Healthcare Conference

PolyPid Ltd. (PYPD) Upgraded to Buy: What Does It Mean for the Stock?

PolyPid Ltd. (NASDAQ:PYPD) Q4 2023 Earnings Call Transcript

PolyPid Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results

PolyPid Announces Enrollment of the 100th Patient in the Ongoing SHIELD II Phase 3 Trial

PolyPid to Report Fourth Quarter and Full-Year 2023 Financial Results and Operational Highlights on February 14, 2024

PolyPid Announces Private Placement for $16 Million in Gross Proceeds

PolyPid Ltd. (NASDAQ:PYPD) Q3 2023 Earnings Call Transcript

PolyPid Provides Corporate Update and Reports Third Quarter 2023 Financial Results

PolyPid Announces the Addition of Dr. Nurit Tweezer-Zaks to its Board of Directors

PolyPid to Report Third Quarter 2023 Financial Results and Operational Highlights on November 8, 2023

PolyPid Regains Compliance with Nasdaq Minimum Closing Bid Price Rule

PolyPid Announces Presentation at the American College of Surgeons Clinical Congress 2023

PolyPid Announces Publication of Preclinical Data Further Supporting the Good Safety Profile of D-PLEX₁₀₀ and PLEX Technology Platform

Performance Overview